Short-Term Lower Leg Growth in 5- to 11-Year-Old Asthmatic Children Using Beclomethasone Dipropionate Inhalers With Chlorofluorocarbon or Hydrofluoroalkane Propellants: A 9-Week, Open-Label, Randomized, Crossover, Noninferiority Study

Wolthers, Ole D.; Walters, Ewan G.

doi:10.1016/j.clinthera.2011.06.015

Cited by 12 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Short-term research has shown a significant slower development in child growth during their 1 st year of life [25]. Unfinished studies conducted in children aged 4-8 years after the completion of a medium dosage of inhaled corticosteroids significantly slowed the development of female children [26], [27].…”

Section: Discussionmentioning

confidence: 99%

Effect of Glucocorticoids Following Application of Adenosine Receptor Blockers in Patients with Chronic Obstructive Bronchitis and Bronchial Asthma

Shabani

Mustafa²,

Islami

et al. 2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

AIM: The effects of the glucocorticoids (GR) fluticasone and budesonide and a blocker of the adenosine receptor in the treatment of patients with chronic obstructive pulmonary disease (COPD) and bronchial asthma were studied in this work. METHODS: The parameters of lung function were determined with body plethysmography. Airway resistance (Raw) was registered and measured and the intrathoracic gas volume and specific resistance (SRaw) of the airways were also calculated. RESULTS: The results of this study of patients with COPD and bronchial asthma used doxofylline as a blocker of the adenosine receptor. Doxofylline was given orally on 7 consecutive days at home with a dose of 2 × 400 mg orally. Raw and IGTV were then measured, and SRaw was calculated. The results indicated a significant decrease in the airway specific resistance (p < 0.05). On the 8th day, the same patients were given two inhalations with spray fluticasone and budesonide (budesonide, 2 inh × 2 mg; Pulmicort 2 inh × 125 mcg). After the inhalations were given, Raw and IGTV were measured after 5, 15, 30, 60, and 120 min, SRaw was then calculated. CONCLUSION: After the preliminary application of doxofylline, the GRs fluticasone and budesonide have a significant effect (p < 0.01) on the decrease of the airway SRaw. This effect suggests that the blocking effect of the adenosine receptor (p < 0.05) emphasizes the bronchodilation effect of GRs (p < 0.01).

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Glucocorticoids Following Application of Adenosine Receptor Blockers in Patients with Chronic Obstructive Bronchitis and Bronchial Asthma

Shabani

Mustafa²,

Islami

et al. 2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…Systemic activity of extra-fine ciclesonide between 40 and 320 lg/day (10,(42)(43)(44)(45)(46) and beclomethasone dipropionate between 80 and 400 lg/day (9,(47)(48)(49) has been assessed by single morning plasma concentrations and Synacthen stimulation of the hypothalamic-pituitary-adrenal axis (42,43,46) and by 12-(43) or 24 (10,46,49)-hour urine cortisol excretion in randomized, double-blind (10,(42)(43)(44)(45)(46)(47)49) and randomized, open designs (48)(49)(50) in pre-pubertal school-age children with asthma. In all studies of ciclesonide except one (44), the pMDI was used without a volume spacer once daily in the evening; the studies in beclomethasone dipropionate used a volume spacer and the pMDI was taken twice daily.…”

Section: Hypothalamic-pituitary-adrenal Functionmentioning

confidence: 99%

“…In all studies of ciclesonide except one , the pMDI was used without a volume spacer once daily in the evening; the studies in beclomethasone dipropionate used a volume spacer and the pMDI was taken twice daily. Most of the studies did not find any effects on cortisol measures be it when compared to placebo or treatment‐free run‐in or when compared to conventional beclomethasone dipropionate in twice the daily dose or to fluticasone propionate . One study in 6‐ to 11‐year‐old children, however, found ciclesonide 80 and 160 μg/day to suppress 24‐h urine cortisol statistically significantly as compared to fluticasone propionate 176 μg/day , and another study compared ciclesonide 160 μg/day to dry powder budesonide 400 μg/day with similar results .…”

Section: Systemic Activitymentioning

confidence: 99%

“…An observer blinded, randomized crossover comparison of extra‐fine hydrofluoroalkane beclomethasone dipropionate 100 μg b.i.d. pMDI with the AeroChamber Plus ™ spacer with chlorofluorocarbon beclomethasone dipropionate 200 μg b.i.d with the Volumatic ™ spacer used a non‐inferiority design in 63 children 5–11 years of age with mild asthma . Extra‐fine beclomethasone dipropionate 100 μg b.i.d.…”

Section: Systemic Activitymentioning

confidence: 99%

See 1 more Smart Citation

Extra‐fine particle inhaled corticosteroids, pharma‐cokinetics and systemic activity in children with asthma

Wolthers¹

2015

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

During recent years, extra-fine particle inhaled corticosteroids with a median aerodynamic diameter ≤2 μm have been introduced in the treatment of asthma. The aim of this paper was to review pharmacokinetics and systemic activity of extra-fine particle hydroalkane pressurized metered dose inhaled (pMDI) ciclesonide and beclomethasone dipropionate in children. A literature review was performed. Systemic bioavailability of oral and pulmonary deposition of extra-fine ciclesonide and beclomethasone dipropionate was 52% and 82%, the half-life in serum 3.2 and 1.5 h and first-pass hepatic metabolism >99% and 60%, respectively. Secondary analyses of urine cortisol/creatinine excretion found no effects of ciclesonide pMDI between 40 and 320 μg/day or of beclomethasone dipropionate pMDI between 80 and 400 μg/day. Ciclesonide pMDI 40, 80 and 160 μg/day caused no effects on short-term lower leg growth rate as assessed by knemometry. Ciclesonide 320 μg/day was associated with a numerically short-term growth suppression equivalent to 30% which was similar to 25% and 36% suppression caused by beclomethasone dipropionate HFA and CFC 200 μg/day, respectively. Consistent with the differences in key pharmacokinetic features, beclomethasone dipropionate is associated with a systemic activity detected by knemometry at a lower dose than ciclesonide. Whether that correlates with a clinically important difference remains to be explored. Assessments of systemic activity of beclomethasone dipropionate <200 μg/day and of ciclesonide >180 μg/day as well as head-to-head comparisons are warranted. Preferably, such studies should apply the sensitive method of knemometry.

show abstract

“…3 Despite having been on the market since the early 1980s for use in children, the potential of inhaled glucocorticoids for suppression of final height, however, has not yet been clarified. This study aimed to answer the question: what happens to adult height in children who present a growth deficit caused by few years’ treatment with inhaled glucocorticoids in childhood?…”

Section: Contextmentioning

confidence: 99%

It is still an open question whether inhaled glucocorticoid-induced effects may reduce adult height

Wolthers

2013

Evid Based Med

View full text Add to dashboard Cite

show abstract

Short-Term Lower Leg Growth in 5- to 11-Year-Old Asthmatic Children Using Beclomethasone Dipropionate Inhalers With Chlorofluorocarbon or Hydrofluoroalkane Propellants: A 9-Week, Open-Label, Randomized, Crossover, Noninferiority Study

Cited by 12 publications

References 14 publications

Effect of Glucocorticoids Following Application of Adenosine Receptor Blockers in Patients with Chronic Obstructive Bronchitis and Bronchial Asthma

Effect of Glucocorticoids Following Application of Adenosine Receptor Blockers in Patients with Chronic Obstructive Bronchitis and Bronchial Asthma

Extra‐fine particle inhaled corticosteroids, pharma‐cokinetics and systemic activity in children with asthma

It is still an open question whether inhaled glucocorticoid-induced effects may reduce adult height

Contact Info

Product

Resources

About